Page 6 - Commodore Capital News Today

Commodore Capital LP bought a new position in shares of Ambrx Biopharma Inc. (NYSE:AMAM – Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 4,803,447 shares of the company’s stock, valued at approximately $42,847,000. Ambrx Biopharma comprises 6.5% […]

Commodore Capital LP raised its holdings in shares of Merus (NASDAQ:MRUS – Free Report) by 8.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,950,000 shares of the biotechnology company’s stock after buying an additional 217,433 shares during the quarter. […]

Commodore Capital LP raised its stake in Celcuity Inc. (NASDAQ:CELC – Free Report) by 4.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,390,772 shares of the company’s stock after buying an additional 62,820 shares during the quarter. Celcuity comprises about 2.2% of […]

Commodore Capital LP increased its holdings in Celcuity Inc. (NASDAQ:CELC – Free Report) by 4.7% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,390,772 shares of the company’s stock after buying an additional 62,820 shares during the period. Celcuity comprises about 2.2% […]

Commodore Capital LP grew its stake in Cabaletta Bio, Inc. (NASDAQ:CABA – Free Report) by 81.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,835,000 shares of the company’s stock after acquiring an additional 824,641 shares during the quarter. Cabaletta […]

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades.

Capital from LPs is drying up—especially for newbies.

Proceeds to Further Advance Company’s Lead Clinical ProgramsSAN DIEGO--(BUSINESS WIRE)--ADARx Pharmaceuticals, Inc. (“ADARx” or “the Company”), a clinical stage biotechnology company developing next generation RNA therapeutics, today announced the successful close of an oversubscribed $200 million Series C financing...

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) CFO Eva Renee Barnett sold 2,725 shares of Immunovant stock in a transaction on Wednesday, July 19th. The shares were sold at an average price of $24.94, for a total transaction of $67,961.50. Following the completion of the sale, the chief financial officer now directly owns 349,863 shares […]